A novel autoantibody against ephrin type B receptor 2 in acute necrotizing encephalopathy
© Shirai et al.; licensee BioMed Central Ltd. 2013
Received: 29 June 2013
Accepted: 1 October 2013
Published: 18 October 2013
Acute necrotizing encephalopathy (ANE) is characterized by symmetrical brain necrosis, suggested to be due to breakdown of the blood–brain barrier (BBB). We experienced a rare case of ANE complicated with systemic lupus erythematosus (SLE), and found that the patient’s serum (V10-5) had binding activity to human umbilical vein endothelial cells (HUVECs). By SARF (Serological identification system for Autoantigens using a Retroviral vector and Flow cytometry) method using V10-5 IgG, a clone bound to V10-5 IgG was isolated. This cell clone was integrated with cDNA identical to EphB2, which plays critical roles in neuronal cells and endothelial cells. HUVECs and human brain microvascular endothelial cells expressed EphB2 and the V10-5 IgG bound specifically to EphB2-transfected cells. Anti-EphB2 antibody was not detected in other SLE patients without ANE. In this report, we identified EphB2 as a novel autoantigen, and anti-EphB2 antibody may define a novel group of brain disorders. Anti-EphB2 antibody can interfere not only with endothelial cells including those of the BBB (acting as an anti-endothelial cell antibody), but also neuronal cells (acting as an anti-neuronal antibody) if the BBB has been breached. Future studies should determine the clinical prevalence and specificity of anti-EphB2 antibody, and the molecular mechanisms by which anti-EphB2 antibody mediates neuronal and vascular pathological lesions.
KeywordsAcute necrotizing encephalopathy Autoantibody Ephrin type B receptor 2 Serological identification system for Autoantigens using a Retroviral vector and Flow cytometry (SARF)
A group of brain disorders involving autoantibodies targeting cell-surface or synaptic proteins has been identified. The antigens include N-methyl-D-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), γ-aminobutyric acid receptor-B (GABAB receptor), leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-like 2 (Caspr2), glycine receptor (GlyR), and metabotropic glutamate receptor mGluR5 .
Autoantibodies cause tissue damage through a number of mechanisms. Especially, cell-surface target antigens are susceptible to disruption by autoantibodies, and syndromes mediated by these autoantibodies often mimic animal models with genetic or pharmacological disruption of these molecules . Identifying these autoantigens would be helpful in understanding the pathophysiology of these syndromes.
Acute necrotizing encephalopathy (ANE) is a rare type of acute encephalopathy first described in Japan. The diagnosis is based on the topographic distribution and evolution of symmetric lesions visualized by computed tomography (CT) and magnetic resonance imaging (MRI) in the bilateral thalami and other specific brain areas . Although the pathogenesis remained obscure, vasculopathy with breakdown of the blood–brain barrier (BBB) was suggested .
Recently, we established a novel method to identify cell-surface autoantigens, which we named Serological identification system for Autoantigens using a Retroviral vector and Flow cytometry (SARF) [4, 5]. Using SARF, we successfully identified ephrin type B receptor 2 (EphB2), which has critical functions in neuronal and endothelial cells (ECs) , as a target of autoantibody from a patient with ANE complicated with systemic lupus erythematosus (SLE).
Source of human serum
Forty-eight patients with SLE (44 female and 4 male patients) diagnosed according to the 1997 revised criteria for the classification  were enrolled in this study. The patients gave written consent after the purpose and potential risks involved in the study were explained. The study protocol complied with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Tohoku University Graduate School of Medicine.
Human umbilical vein ECs (HUVECs), Plat-E packaging cells, rat myeloma cells: YB2/0, and medium were purchased and grown as described previously . Human brain microvascular ECs (HBMECs) and medium were purchased from Cell Systems (Kirkland, WA, USA).
Binding activities of antibodies to the surface of ECs and EphB2 were measured and analyzed as described previously . Briefly, aliquots of 1 × 105 cells/tube were incubated in blocking buffer with primary antibodies at 4°C for 30 minutes. After washing, cells were incubated with secondary antibodies and 7-amino-actinomycin D (7-AAD) (BD Biosciences, Bedford, MA, USA) at 4°C for 30 minutes and analyzed by flow cytometry.
Goat anti-human EphB2 antibody was purchased from R&D Systems (Minneapolis, MN, USA), and recombinant EphB2 was purchased from Sino Biological (Beijing, China).
Generation of HUVEC cDNA library and screening of cDNA were performed as described previously . Briefly, the HUVEC cDNA library was retrovirally transfected into the YB2/0 cells. YB2/0 cells expressing the HUVEC cDNA library were incubated with serum IgG and fluorescein isothiocyanate (FITC)-labeled secondary antibody. Cells showing a high level of FITC fluorescence were sorted with FACSAriaII (Becton Dickinson, Franklin Lakes, NJ, USA). Sorted cells were kept in culture until the cell number increased sufficiently for the next round of sorting. Subcloning of cells was performed by the limiting dilution method. Total RNAs of cloned cells and unsorted cells were generated and subjected to microarray analysis (GeneChip Human Genome U133 Plus 2.0 Array; Affymetrix, Santa Clara, CA, USA).
Expression of EphB2 in YB2/0 cells
The full-length EphB2 fragment was amplified by PCR from genomic DNA of EphB2-expressing YB2/0 clone sorted as described above, using Phusion High-Fidelity DNA Polymerase (Finnzymes, Keilaranta, Espoo, Finland). Primer sequences were as follows: 5′-AAGCGCAGCCATGGCTCT-3′, 3′-AGGCAGGTGAATGTCAAACC-5′. EphB2 fragment was inserted into the pMX-IRES-GFP vector (Cell Biolabs, San Diego, CA, USA).
Case of ANE complicated with SLE
Identification of EphB2 as a novel cell-surface autoantigen
Microarray analysis of unsorted YB-2/0 and C17 indicated that the signal of EphB2 was significantly increased (26.16-fold) in C17 compared to unsorted cells, and we confirmed that the EphB2 cDNA was inserted into the genomic DNA of the V10-5-C17 clone by PCR (Figure 2D). We also confirmed the expression of EphB2 on the V10-5-C17 clone by flow cytometry (Figure 2E). Next, we generated an expression vector for EphB2, which was transfected into YB2/0 cells. V10-5 IgG showed significant binding activity to EphB2-expressing YB2/0 cells (Figure 2F), indicating that V10-5 IgG has anti-EphB2 activity. Thus, EphB2 was identified as a novel autoantigen in a patient with ANE complicated with SLE.
Although we measured anti-EphB2 activity among 47 SLE patients (nine patients had been diagnosed with NPSLE, none of them presented ANE) who had AECA activities, anti-EphB2 antibody was not detected in any other SLE patients examined.
Identification of EphB2 as a novel autoantigen may be important in clarifying the pathogenesis of ANE because anti-EphB2 antibody has potential to play pathogenic roles in neuronal and vascular lesions.
ANE has a high mortality rate and is usually preceded by infections, such as influenza, with the signs of brain dysfunction appearing a few days later . It is characterized by symmetrical brain necrosis, which involves the thalamus followed by the tegmentum of the pons and other regions, and these are demonstrated by CT and MRI . Neuropathologically, the lesions tend to spread along small blood vessels, and the extent of the lesions appears to be determined by the spread of edema fluid. These observations indicate the vasogenic nature of edema-necrosis in ANE, resulting from local breakdown of the BBB . EC necrosis and inflammatory fibrinoid vasculitis have also been reported .
Although our patient showed characteristic features of ANE, this is a very rare complication of SLE; to our knowledge, no other cases of SLE manifesting ANE have been reported to date. Although some previous reports indicated the absence of ANA in ANE , the correlation between SLE and ANE is uncertain.
Eph receptors belong to one of the largest families of tyrosine kinases. They are known to have diverse functions in neural development, cell morphogenesis, tissue patterning, angiogenesis, and neural plasticity . Among them, the critical roles of EphB2 in the nervous system have recently been clarified. The important functions of EphB2 include regulation of NMDAR-dependent Ca2+ influx and downstream transcription factors in neuronal cells , and the involvement in neurological diseases, including Alzheimer’s disease, anxiety, and anti-NMDA encephalitis has been reported [11–13]. We performed an immunohistochemical study of mouse brain tissues using a commercially available anti-EphB2 antibody. As a result, we identified positive reactions on neural cells and glia in the cerebral cortex and also ECs in the subarachnoid regions (data not shown). Further studies would be done to investigate whether the reactivity of the patient’s antibodies with brain is abrogated by immunoadsorption with EphB2 or in EphB2 knockout mice tissues. Interestingly, EphB2 is also expressed on ECs and is required for EC formation of cord-like structures .
Thus, anti-EphB2 antibody could potentially interfere not only with ECs including those of the BBB (acting as an AECA), but also neuronal cells (acting as an anti-neuronal antibody) if the BBB has been breached. Taken together, the possible suspected pathomechanisms are 1) anti-EphB2 antibody damages vascular ECs, which results in breakdown and increased permeability of BBB; 2) anti-EphB2 antibody exudated into brain tissue binds neurons and glia, which causes neuronal dysfunction and brain necrosis.
In the present study, anti-EphB2 antibody was not detected in any other patients with SLE, none of whom manifested ANE. Although we did not evaluate the prevalence of anti-EphB2 antibody in other ANE patients because of its rarity, anti-EphB2 antibody may define a novel group of brain disorders the clinical manifestations of which are similar to those of ANE. If this is the case, anti-EphB2 antibody may be a useful biomarker, and provide new insight into such brain disorders.
We identified EphB2 as a novel autoantigen in a patient with ANE complicated with SLE. Anti-EphB2 antibody may have dual activity as an AECA and an anti-neuronal antibody. Further studies are needed to determine the clinical prevalence and specificity of anti-EphB2 antibody, and the molecular mechanisms by which anti-EphB2 antibody mediates neuronal and vascular pathological lesions.
Written informed consent was obtained from the next of kin of this patient for publication of this case report and any accompanying images because consciousness of this patient did not recover. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Anti-endothelial cell antibody
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
Acute necrotizing encephalopathy
Contactin-associated protein-like 2
Ephrin type B receptor 2
γ-aminobutyric acid receptor-B
Human brain microvascular endothelial cells
Human umbilical vein endothelial cells
Leucine-rich glioma-inactivated protein 1
Metabotropic glutamate receptor
Magnetic resonance imaging
Neuropsychiatric systemic lupus erythematosus
Polymerase chain reaction
Serological identification system for Autoantigens using a Retroviral vector and Flow cytometry
Systemic lupus erythematosus
We thank the staff of the Department of Hematology and Rheumatology, and the Department of Neurology, Tohoku University, for help and discussion.
- Lancaster E, Dalmau J: Neuronal autoantigens - pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012, 8: 380-390. 10.1038/nrneurol.2012.99.PubMed CentralView ArticlePubMedGoogle Scholar
- Mastroyianni SD, Gionnis D, Voudris K, Skardoutsou A, Mizuguchi M: Acute necrotizing encephalopathy of childhood in non-Asian patients: report of three cases and literature review. J Child Neurol. 2006, 21: 872-879. 10.1177/08830738060210101401.View ArticlePubMedGoogle Scholar
- Spalice A, Del Balzo F, Nicita F, Papetti L, Ursitti F, Salvatori G, Zicari AM, Properzi E, Duse M: Teaching NeuroImages: acute necrotizing encephalopathy during novel influenza A (H1N1) virus infection. Neurology. 2011, 77: e121-10.1212/WNL.0b013e318238ee56.View ArticlePubMedGoogle Scholar
- Shirai T, Fujii H, Ono M, Nakamura K, Watanabe R, Tajima Y, Takasawa N, Ishii T, Harigae H: A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus. Arthritis Res Ther. 2012, 14: R157-10.1186/ar3897.PubMed CentralView ArticlePubMedGoogle Scholar
- Shirai T, Fujii H, Ono M, Watanabe R, Ishii T, Harigae H: An innovative method to identify autoantigens expressed on the endothelial cell surface: serological identification system for autoantigens using a retroviral vector and flow cytometry (SARF). Clin Dev Immunol. 2013, 2013: 453058.PubMed CentralView ArticlePubMedGoogle Scholar
- Pasquale EB: Eph receptor signaling casts a wide net on cell behavior. Nat Rev Mol Cell Biol. 2005, 6: 462-475. 10.1038/nrm1662.View ArticlePubMedGoogle Scholar
- Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725.View ArticlePubMedGoogle Scholar
- Mizuguchi M, Abe J, Mikkaichi K, Noma S, Yoshida K, Yamanaka T, Kamoshita S: Acute necrotizing encephalopathy of childhood: a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry. 1995, 58: 555-561. 10.1136/jnnp.58.5.555.PubMed CentralView ArticlePubMedGoogle Scholar
- Ng WF, Chiu SC, Lam DS, Wong YC, Tam S, Kwong NS, Loo KT, Yuen KY: A 7-year-old boy dying of acute encephalopathy. Brain Pathol. 2010, 20: 261-264. 10.1111/j.1750-3639.2009.00346.x.View ArticlePubMedGoogle Scholar
- Takasu MA, Dalva MB, Zigmond RE, Greenberg ME: Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science. 2002, 295: 491-495. 10.1126/science.1065983.View ArticlePubMedGoogle Scholar
- Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L: Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011, 469: 47-52. 10.1038/nature09635.PubMed CentralView ArticlePubMedGoogle Scholar
- Attwood BK, Bourgognon JM, Patel S, Mucha M, Schiavon E, Skrzypiec AE, Young KW, Shiosaka S, Korostynski M, Piechota M, Przewlocki R, Pawlak R: Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature. 2011, 473: 372-375. 10.1038/nature09938.PubMed CentralView ArticlePubMedGoogle Scholar
- Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, Meissirel C, Honnorat J, Groc L: Disrupted surface cross-talk between NMDA and ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012, 135: 1606-1621. 10.1093/brain/aws092.View ArticlePubMedGoogle Scholar
- Salvucci O, de la Luz SM, Martina JA, McCormick PJ, Tosato G: EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood. 2006, 108: 2914-2922. 10.1182/blood-2006-05-023341.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.